These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3094926)

  • 21. The ethical issues of the postmarketing surveillance of drug teratogenicity in Hungary.
    Czeizel AE
    Pharmacoepidemiol Drug Saf; 2001 Dec; 10(7):635-9. PubMed ID: 11980253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Counseling adolescents about environmental teratogens.
    Williams JK
    Pediatr Nurs; 1986; 12(4):292-5, 304. PubMed ID: 3637772
    [No Abstract]   [Full Text] [Related]  

  • 23. Blood dyscrasias and the pharmaceutical industry: screening surveillance and monitoring, and future drug development.
    Eur J Haematol Suppl; 1996; 60():128-9. PubMed ID: 8987256
    [No Abstract]   [Full Text] [Related]  

  • 24. Drug labeling for teratogenicity: requirements of the U.S. Food and Drug Administration.
    Kelsey FO
    Prog Clin Biol Res; 1985; 163C():155-9. PubMed ID: 3991617
    [No Abstract]   [Full Text] [Related]  

  • 25. Human teratogens and evidence-based teratogen risk counseling: the Motherisk approach.
    Nava-Ocampo AA; Koren G
    Clin Obstet Gynecol; 2007 Mar; 50(1):123-31. PubMed ID: 17304029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Principles and concepts of teratogenesis. I. The teratogenic injury (author's transl)].
    Rooze M
    Rev Med Brux; 1980 Oct; 1(8):523-33. PubMed ID: 6781025
    [No Abstract]   [Full Text] [Related]  

  • 27. [Tumor therapy and family planning].
    Theile U; Rapp E
    Med Klin (Munich); 1996 Jun; 91(6):402-9. PubMed ID: 8767316
    [No Abstract]   [Full Text] [Related]  

  • 28. The rationale for a post-marketing surveillance.
    Westerholm B
    Hum Reprod; 1987 Jan; 2(1):41-4. PubMed ID: 3571446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Description and mission evaluation of the Hungarian case-control surveillance of congenital abnormalities, 1980-1996.
    Czeizel AE; Rockenbauer M; Siffel C; Varga E
    Teratology; 2001 May; 63(5):176-85. PubMed ID: 11320528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Postmarketing surveillance of medications and pregnancy outcomes: clarithromycin and birth malformations.
    Drinkard CR; Shatin D; Clouse J
    Pharmacoepidemiol Drug Saf; 2000 Dec; 9(7):549-56. PubMed ID: 11338912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical testing for teratogenicity and developmental toxicity: methods and limitations.
    Barrow PC
    Therapie; 2002; 57(2):109-14. PubMed ID: 12185956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of the nonsteroidal anti-inflammatory drug literature for potential developmental toxicity in rats and rabbits.
    Cook JC; Jacobson CF; Gao F; Tassinari MS; Hurtt ME; DeSesso JM
    Birth Defects Res B Dev Reprod Toxicol; 2003 Feb; 68(1):5-26. PubMed ID: 12852480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drugs in pregnancy and their effects on pre- and postnatal development.
    Kelsey FO
    Res Publ Assoc Res Nerv Ment Dis; 1973; 51():233-43. PubMed ID: 4590403
    [No Abstract]   [Full Text] [Related]  

  • 34. Drug and other hazards to the fetus and newborn.
    Freeman MM; Finkel MJ
    Prog Clin Biol Res; 1980; 36():67-72. PubMed ID: 7403181
    [No Abstract]   [Full Text] [Related]  

  • 35. Improper interpretation of data concerning teratogenicity: a case report.
    Staples RE
    Prog Clin Biol Res; 1985; 163C():161-3. PubMed ID: 3921981
    [No Abstract]   [Full Text] [Related]  

  • 36. Monitoring adverse drug reactions in the postmarketing phase.
    Hoigné R; Hottinger S
    Pharm Acta Helv; 1988; 63(1):2-12. PubMed ID: 3283774
    [No Abstract]   [Full Text] [Related]  

  • 37. Using the Hungarian Birth Defects Registry for surveillance, research and intervention.
    Siffel C; Czeizel AE
    Cent Eur J Public Health; 1997 Jun; 5(2):79-81. PubMed ID: 9208163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postmarketing surveillance.
    Oleen MA
    Can J Hosp Pharm; 1987 Oct; 40(5):171-2, 179-80. PubMed ID: 10284449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Iatrogenic diseases linked to the use of drugs and common medical equipment].
    Carpentier F
    Rev Prat; 2001 Apr; 51(7):769-73. PubMed ID: 11387675
    [No Abstract]   [Full Text] [Related]  

  • 40. Accurate information on drug effects on pregnancy is crucial.
    Uhl K; Kennedy DL; Kweder SL
    Am Fam Physician; 2003 Feb; 67(4):700-1; author reply 702. PubMed ID: 12613724
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.